![]() ![]() ![]() Perna, currently head of the US Army Material Command (AMC), the main provider of resources. The logistics of vaccine delivery is being overseen by General Gustave F. Slaoui subsequently resigned from Moderna’s board and has reportedly sold his stake in the company, pledging to donate any additional profit from the recent spike in Moderna’s shares to medical research. The research side of Operation Warp Speed is being led by former GlaxoSmithKline vaccines chief Moncef Slaoui, who courted controversy last month when it emerged he had major stock holdings in Moderna, whose mRNA vaccine is currently furthest ahead in development. That leaves out the big collaboration between Sanofi and GlaxoSmithKline, as well as candidates from US biotechs Inovio and NovaVax whose vaccines are already in the clinic, unlike for example the Merck and J&J programmes. The finalists are candidates from Moderna, Johnson & Johnson, Oxford University and AstraZeneca, Pfizer/BioNTech and Merck & Co, according to a New York Times report. The $10 billion effort to rapidly produce and distribute any coronavirus vaccine that proves effective in clinical testing - first unveiled last month – sifted through 14 top candidates announced last month and has narrowed down the field to five. President Donald Trump’s Operation Warp Speed, which aims to make a coronavirus vaccine widely available by year-end, has come up with a shortlist of candidates, with some notable exclusions. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |